Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GRNDaD Cohort | Patients with sickle cell disease (SCD) who were included in the GRNDaD registry and received a disease modifying therapy (DMT). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry who Received a Disease Modifying Therapy (DMT) | DMTs included: hydroxyurea, voxelotor, crizanlizumab, l-glutamine, and chronic red cell transfusion. | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients in the Globin Research Network for Data and Discovery (GRNDaD) Registry Using Hydroxyurea Categorized by Gender | Up to 2 years | |
| Number of Patients in the GRNDaD Registry Using Hydroxyurea Categorized by Genotype | Up to 2 years |
Not provided
Inclusion criteria:
Exclusion criteria:
• None identified at this time.
Not provided
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of Patients in the GRNDaD Registry Using Hydroxyurea Categorized by Age | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Gender | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Genotype | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Voxelotor Categorized by Age | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Gender | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Genotype | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Crizanlizumab Categorized by Age | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Gender | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Genotype | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using L-glutamine Categorized by Age | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Gender | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Genotype | Up to 2 years |
| Number of Patients in the GRNDaD Registry Using Chronic Transfusion Categorized by Age | Up to 2 years |
| Number of Hospital Admissions Categorized by Age | Up to 2 years |
| Mean Number of Hospital Admissions | Up to 2 years |
| Number of Emergency Department Visits Categorized by Age | Up to 2 years |
| Mean Number of Emergency Department Visits | Up to 2 years |
| D006425 |
| Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |